Genmab

Biotechnology company specializing in antibody therapeutics for cancer and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New antibody tested against aggressive blood cancer Results expected Sep 2026 (estimated) May already have reported ↗
• New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial Results expected Feb 2027 (estimated)
• Outpatient immunotherapy tested for hard-to-treat lymphomas Results expected Mar 2027 (estimated) May already have reported ↗
• Can an antibody drug boost standard chemotherapy against an aggressive blood cancer? Results expected Jun 2027 (estimated) May already have reported ↗
• New drug Rina-S shows promise in battling Hard-to-Treat cancers Results expected Jul 2027 (estimated)